Next generation kinase inhibitors
with unique properties

Potent and selective Nanocyclix leads for known

and novel kinases.

 

New partnering opportunity:  Nanocyclix RIPK2 inhibitors

for use in auto-immune diseases

 

READ MORE

Our ambition

Pave the way for a truly personalized approach in cancer.

 

 READ MORE

Translational biomarker approaches
to address patient needs

Pharmaco-imaging in support of therapeutic development

and for drug targeting.

 

 

READ MORE

State-of-the-art models for optimal
predictive value

Patient-derived xenografts and human immune system

models to allow better decisions.

 

 

READ MORE

We partner to advance cancer
research

Creative partnerships to drive development for oncology

and other serious illnesses with no known effective treatment.

 

READ MORE

December 1st, 2016
Oncodesign completes the acquisition François Hyafil Research Centre and appoints two new strategic activity directors
READ MORE
November 21th, 2016
ONCODESIGN wins the 4th European Small and Mid-Cap Awards in the “Rising Star” category
READ MORE

ONCOLOGY TRANSLATIONAL

EXPERIMENTATION

A large panel of technological and scientific solutions for pharmacological qualification of your compounds : a unique oncology preclinical CRO

DISCOVERY PARTNERING

 

A platform-based approach for the discovery of novel chemical entities with therapeutic and diagnostic potential